Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories.
BACKGROUND
To ensure quality human epidermal growth receptor 2 (HER2) testing in breast cancer, the American Society of Clinical Oncology/College of American Pathologists guidelines were introduced with expected compliance by 2008.


OBJECTIVE
To assess the effect these guidelines have had on pathology laboratories and their ability to address key components.


METHODS
In late 2008, a survey was distributed with the HER2 immunohistochemistry (IHC) proficiency testing program. It included questions regarding pathology practice characteristics and assay validation using fluorescence in situ hybridization or another IHC laboratory assay and assessed pathologist HER2 scoring competency.


RESULTS
Of the 907 surveys sent, 757 (83.5%) were returned. The median laboratory accessioned 15 000 cases and performed 190 HER2 tests annually. Quantitative computer image analysis was used by 33% of laboratories. In-house fluorescence in situ hybridization was performed in 23% of laboratories, and 60% of laboratories addressed the 6- to 48-hour tissue fixation requirement by embedding tissue on the weekend. HER2 testing was performed on the initial biopsy in 40%, on the resection specimen in 6%, and on either in 56% of laboratories. Testing was validated with only fluorescence in situ hybridization in 47% of laboratories, whereas 10% of laboratories used another IHC assay only; 13% used both assays, and 12% and 15% of laboratories had not validated their assays or chose "not applicable" on the survey question, respectively. The 90% concordance rate with fluorescence in situ hybridization results was achieved by 88% of laboratories for IHC-negative findings and by 81% of laboratories for IHC-positive cases. The 90% concordance rate for laboratories using another IHC assay was achieved by 80% for negative findings and 75% for positive cases. About 91% of laboratories had a pathologist competency assessment program.


CONCLUSIONS
This survey demonstrates the extent and characteristics of HER2 testing. Although some American Society of Clinical Oncology/College of American Pathologists guidelines have been implemented, gaps remain in validation of HER2 IHC testing.
Nakhleh
Raouf E
RE
Department of Pathology, Mayo Clinic Florida, Jacksonville, FL 32224, USA. Nakhleh.roauf@mayo.edu
Grimm
Erin E
EE
Idowu
Michael O
MO
Souers
Rhona J
RJ
Fitzgibbons
Patrick L
PL
D017408:Guidelines as Topic / Q000592:standards; D019538:Health Care Surveys; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D007753:Laboratories / Q000592:standards*; D008495:Medical Oncology / Q000592:standards*; D010340:Pathology, Surgical / Q000592:standards*; D011787:Quality of Health Care; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism*; D012044:Regression Analysis; D013048:Specimen Handling; D011795:Surveys and Questionnaires
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human